Indian J Urol. 2010 Jul;26(3):379-84. doi: 10.4103/0970-1591.70576.
Sacral neuromodulation: Therapy evolution.
Indian journal of urology : IJU : journal of the Urological Society of India
Jannah H Thompson, Suzette E Sutherland, Steven W Siegel
Affiliations
Affiliations
- Metropolitan Urology, Cornerstone Medical Specialty, 6025 Lake Road, Suite 100, Woodbury, MN, USA.
PMID: 21116359
PMCID: PMC2978439 DOI: 10.4103/0970-1591.70576
Abstract
OBJECTIVES: Sacral neuromodulation has gained increased worldwide acceptance as the standard of care in patients with refractory overactive bladder (OAB) and non-obstructive urinary retention (NOUR). This review will detail the evolution of the technology.
MATERIALS AND METHODS: The mechanism of action and advances in treatment, including tined lead, fluoroscopic imaging, and smaller implantable pulse generator (IPG) are reviewed. This discussion also explores expanding indications and future advances including interstitial cystitis, chronic pelvic pain, neurogenic bladder, fecal incontinence, constipation, and dysfunctional elimination syndrome in children.
RESULTS: Sacral neuromodulation (SNM) exerts its influence by modulation of sacral afferent inflow on storage and emptying reflexes. The tined lead allows for placement and stimulation to be performed in the outpatient setting under local anesthesia with mild sedation. Lead migration has been minimal and efficacy improved. The use of fluoroscopy has improved accuracy of lead placement and has led to renewed interest in bilateral percutaneous nerve evaluation (PNE). Bilateral PNE can be performed in the office setting under local anesthesia, making a trial of therapy less expensive and more attractive to patients. A smaller IPG has not only improved cosmesis, but decreased local discomfort and need for revision. The role for SNM continues to expand as clinical research identifies other applications for this therapy.
CONCLUSIONS: Our understanding of SNM, as well as technological advances in therapy delivery, expands the pool of patients for which this form of therapy may prove beneficial. Less invasive instrumentation may even make this form of therapy appealing to patients without refractory symptoms.
Keywords: Refractory overactive; neuromodulation; non-obstructive
References
- Urology. 2007 Dec;70(6):1069-73; discussion 1073-4 - PubMed
- BJU Int. 2009 Jun;103(11):1509-15 - PubMed
- Urol Clin North Am. 2005 Feb;32(1):59-63 - PubMed
- J Urol. 2007 Nov;178(5):2029-34 - PubMed
- Eur Urol. 2006 Mar;49(3):519-27 - PubMed
- Mol Med Today. 1996 Oct;2(10):418-24 - PubMed
- Neurourol Urodyn. 2005;24(7):643-7 - PubMed
- Mayo Clin Proc. 2003 Jun;78(6):687-95 - PubMed
- Urology. 2001 Jun;57(6 Suppl 1):124 - PubMed
- Urology. 2004 Mar;63(3):461-5 - PubMed
- Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005493 - PubMed
- Neurourol Urodyn. 2007;26(1):19-28; discussion 36 - PubMed
- Invest Urol. 1979 Sep;17(2):130-4 - PubMed
- J Urol. 1988 Dec;140(6):1331-9 - PubMed
- Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005429 - PubMed
- J Urol. 2003 Nov;170(5):1905-7 - PubMed
- Dis Colon Rectum. 2009 Jan;52(1):11-7 - PubMed
- J Urol. 2005 Dec;174(6):2268-72 - PubMed
- BJU Int. 2003 Mar;91(4):355-9 - PubMed
- Eur Urol. 2008 Dec;54(6):1287-96 - PubMed
- Urology. 1997 Mar;49(3):358-62 - PubMed
- Indian J Urol. 2007 Apr;23(2):166-73 - PubMed
- J Urol. 2008 Jul;180(1):306-11; discussion 311 - PubMed
Publication Types